Evidence map›Paper›PMID 36183571›Full record

ArticleJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2022

Regional Cerebral Small Vessel Disease (rCSVD) Score: A clinical MRI grading system validated in a stroke cohort.

Saman Hazany, Kim-Lien Nguyen, Martin Lee, Andrew Zhang, Parsa Mokhtar, Alexander Crossley, Sakshi Luthra, Pooja Butani, Sunita Dergalust, Benjamin Ellingson and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Saman HazanyDepartment of Radiology, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, USA. Electronic address: saman.hazany@va.gov.
Kim-Lien NguyenDivision of Cardiology and Radiology, VA Greater Los Angeles Healthcare System and David, Geffen School of Medicine at UCLA, USA.
Martin LeeDepartment of Biostatistics, Fielding School of Public Health at UCLA, USA.
Andrew ZhangDepartment of Radiology, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, USA.
Parsa MokhtarDepartment of Psychobiology, University of California Los Angeles, USA.
Alexander CrossleyDepartment of Neurology, VA Greater Los Angeles Healthcare System and David Geffen, School of Medicine at UCLA, USA.
Sakshi LuthraCollege of Letters and Sciences, University of California Los Angeles, USA.
Pooja ButaniDepartment of Neurology, VA Greater Los Angeles Healthcare System and David Geffen, School of Medicine at UCLA, USA.
Sunita DergalustDepartment of Pharmacy, VA Greater Los Angeles Healthcare System, USA.
Benjamin EllingsonDepartment of Radiology and Psychiatry, David Geffen School of Medicine at UCLA, USA.
Jason D HinmanDepartment of Neurology, VA Greater Los Angeles Healthcare System and David Geffen, School of Medicine at UCLA, USA.
VA Greater Los Angeles Healthcare System · USUniversity of California, Los Angeles · USFielding Graduate University · US

Funding

DISCOVERY - Statistics and Analysis CoreU19NS115388 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg, Natalia S Rost · 2019 to 2026
$75.4M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert M Prins · 2017 to 2026
$25.2M
Women's Health and Functional Visceral Disorders CenterP50DK064539 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 2002 to 2017
$17.5M
Ferumoxytol-Enhanced Cardiac MRI for Ischemic Heart DiseaseR01HL148182 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NGUYEN, KIM-LIEN T · 2020 to 2024
$3.8M
Spinal and Cerebral biomarkers for measuring disease progression and prognosis in chronic spinal cord injuryR01NS078494 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M., HOLLY, LANGSTON TYLER · 2012 to 2022
$3.6M
Novel imaging and endothelial biomarkers of small vessel cerebrovascular diseaseUH3NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DECARLI, CHARLES, KRAMER, JOEL H · 2018 to 2020
$3.5M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
Tailoring Stress Cardiac MRI for Women with Ischemic Heart DiseaseI01CX001901 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI NGUYEN, KIM-LIEN T · 2019 to 2025
–
CSRD VA I01 CX001901EPA EP-C-15-003NCI NIH HHS P50 CA211015NCI NIH HHS R21 CA223757NHLBI NIH HHS R01 HL148182NIDDK NIH HHS P50 DK064539NINDS NIH HHS R01 NS078494NINDS NIH HHS U19 NS115388NINDS NIH HHS UH3 NS100608
6 · The paper itself

Abstract

backgroundCurrent methods for quantitative assessment of cerebral small vessel disease (CSVD) ignore critical aspects of the disease, namely lesion type and regionality. We developed and tested a new scoring system for CSVD, "regional Cerebral Small Vessel Disease" (rCSVD) based on regional assessment of magnetic resonance imaging (MRI) features.

methods141 patients were retrospectively included with a derivation cohort of 46 consecutive brain MRI exams and a validation cohort of 95 patients with known cerebrovascular disease. We compared the predictive value of rCSVD against existing scoring methods. We determined the predictive value of rCSVD score for all-cause mortality and recurrent strokes.

results46 (44 male) veteran patients (age: 66-93 years), were included for derivation of the rCSVD score. A non-overlapping validation cohort consisted of 95 patients (89 male; age: 34-91 years) with known cerebrovascular disease were enrolled. Based on ROC analysis with comparison of AUC (Area Under the Curve), "rCSVD" score performed better compared to "total SVD score" and Fazekas score for predicting all-cause mortality (0.75 vs 0.68 vs 0.69; p = 0.046). "rCSVD" and total SVD scores were predictive of recurrent strokes in our validation cohort (p-values 0.004 and 0.001). At a median of 5.1 years (range 2-17 years) follow-up, Kaplan-Meier survival analysis demonstrated an rCSVD score of 2 to be a significant predictor of all-cause-mortality.

conclusion"rCSVD" score can be derived from routine brain MRI, has value in risk stratification of patients at risk of CSVD, and has potential in clinical trials once fully validated in a larger patient cohort.

Indexed as

Cerebral Small Vessel DiseasesStrokeAdultAgedAged, 80 and overBrainHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesCardiovascular healthCerebral microbleedCerebral microvascular diseaseCerebral small vessel diseaseCSVDLacunar infarctsMRIRecurrent strokeRegional CSVD

Identifiers

PMID36183571
PMCPMC10163829
OpenAlexW4297991812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.